The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1183 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 27 July 2017 | Suspended. Company has advised that they will not be pursuing a licensing application for bevacizumab from the European Medicines Authority for this indication at this time. |
| 27 July 2017 | The Department of Health has asked NICE to conduct a Single Technology Appraisal of bevacizumab within its marketing authorisation for malignant pleural Mesothelioma. However, the company have advised that they will not be pursuing a licensing application for bevacizumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual